The Peptide Vote and What It Changes

On July 23rd and 24th, fourteen people sat in a conference room in Maryland and voted on whether six peptides should become legal for a pharmacy to compound. They said yes to six of seven. The FDA’s own scientists had recommended against all seven of them, every single one. If you’re holding a vial of BPC-157, or you’ve been waiting to see whether a pharmacy could finally hand you one instead of a website, here’s your answer: the vote matters, and nothing about your options changed that week.

Both of those things are true at the exact same time, which is exactly where all the confusion comes from.

The committee in question is the Pharmacy Compounding Advisory Committee: a standing panel of outside experts who advise the FDA on what compounding pharmacies are allowed to make. Compounding, in plain terms, is a pharmacy mixing up a drug to order for one specific patient instead of dispensing something mass-produced off a shelf. What a pharmacy can legally compound from is set by a federal roster called the 503A bulk drug substances list, named for the section of law behind it. Landing on that list is the thing that would make these peptides available by prescription.

The committee does not control that list. It recommends. That’s the whole job.

What happenedFourteen People, Seven Votes

Over two days, the panel worked through all seven substances, one at a time. Each one got a presentation. Each one got a discussion. Each one got a vote.

• BPC-157 8to6 1 abstained Recommended
• KPV 8to6 1 abstained Recommended
• TB-500 8to6 1 abstained Recommended
• MOTS-c 7to5 2 abstained Recommended
• Epitalon 7to5 1 abstained Recommended
• Semax 8to5 none abstained Recommended
• Emideltide (DSIP) 6to7 1 abstained Not recommended

In favour Against Against, where it carried

The margins were tight. The widest one was two votes. On a fourteen-person panel, one or two people changing their minds flips most of these results. It’s easy to read a result like this as a green light. Read it again: a two-vote margin, with abstentions sprinkled in, is a room that was basically split down the middle.

The dissentWhat the FDA’s Own Scientists Said

The FDA employs career scientists whose entire job is evaluating substances like these and writing the briefing documents before the meeting happens. On all seven peptides, their recommendation was the same: against.

Their objections were never about whether the compounds are interesting. They were about the stuff that decides whether a pharmacy can safely make something. Incomplete chemical characterisation, meaning nobody can always say for certain exactly what’s in the powder. Possible impurities from manufacturing. The risk of an immune reaction to an injected peptide, a known hazard of this entire class of drug. And thin published evidence for the exact uses people want these for.

The panel voted the other way anyway. That’s allowed. That’s literally the point of an advisory committee: bring outside judgment into the room. Disagreeing with staff reviewers happens more often than most people assume. But let’s not dance around what that means. A recommendation made over the objection of the people who read the underlying data does not carry the same weight as one made with their backing.

A two-vote margin, against the advice of the people who read the file, does not settle an argument. It leaves one wide open.

The mechanicsWhat This Vote Cannot Do

The committee’s vote does not add one single thing to the 503A list. It can’t. Adding a substance means the FDA has to go through notice-and-comment rulemaking, and that process has a fixed shape, no shortcuts:

The agency reviews the recommendation. It publishes a proposed rule. It opens a public comment period, where literally anyone can file evidence or an objection. It reads every comment. Then, and only then, it issues a final rule, one that may or may not match a single thing the committee suggested.

Attorneys who work this exact corner of the law put the realistic timeline at roughly eight to twelve months, and the FDA has announced no deadline of its own. It’s also completely free to land somewhere different from what its advisers suggested. The vote is a recommendation sitting on the record. Nothing more. And the record now holds both that recommendation and the staff objection sitting right next to it.

So here’s where things stand: today looks exactly like June did. These peptides are not approved drugs. They are not on the compounding list. A pharmacy that makes one for you right now is not operating under any rule that permits it. Full stop.

If it holdsWhat Changes If This Rule Lands

Say the FDA follows the recommendation and the rule gets finalised. What changes is the channel these compounds come through. The chemistry never moves an inch.

Right now the common route is a website selling you a vial labelled research-use-only, a legal category that means it’s sold as a laboratory material, not as something meant to go in your body. You’re buying from a supplier whose quality control you cannot inspect. There’s no clinician standing between you and that decision. Just you, a browser tab, and a checkout button.

Under a finalised rule, a licensed compounding pharmacy could prepare that same peptide against a prescription instead. That means a pharmacist who’s responsible for the preparation. A facility that gets inspected. Sourcing rules for the raw material. A prescriber who has to justify writing the prescription in the first place and who can see the rest of your medical picture, not just the one thing you’re asking for. For anyone taking these compounds either way, that’s a meaningfully safer setup. It’s also the strongest argument the yes votes had.

What it would not do is make any of these compounds proven. A pharmacy being allowed to prepare something is a statement about manufacturing and oversight. Full stop. It is not, and never will be, a finding that the substance works.

UnchangedNothing About the Evidence Changed

A regulatory vote is dangerously easy to mistake for a scientific one. They are not the same thing, not even close.

Nothing got discovered in that conference room. No trial reported out. Not one. BPC-157 has the exact literature it had back in June: striking results in rodent tendon, ligament, and gut models, and human trials for those specific uses that remain genuinely rare. TB-500, MOTS-c, and KPV are all sitting in the same spot: promising in animals, thin in people. Epitalon and Semax rest mostly on small Russian and Soviet-era studies that nobody has independently replicated.

Our peptide library grades all seven compounds on the exact same scale it used last month, because the thing that scale measures never moved. If a compound was preclinical in June, it’s preclinical now. A committee vote is not evidence. It’s a vote.

What to watchThree Things to Watch Next

A proposed rule in the Federal Register. This is the first real signal, the first one that counts. It will spell out what the FDA intends to do and why, and it’s the first moment the agency’s position goes public instead of getting guessed at by everybody with an opinion.

The comment period. Anyone can file, and plenty of people will. Manufacturers will show up. Clinicians will show up. So will people who have taken these compounds themselves. What gets submitted there, especially any new safety data, tends to shape the final rule more than the advisory vote ever did.

The final rule. Still months out. The only step in this whole process that changes what a pharmacy may legally do.

Until then, these compounds get bought exactly the way they were bought in June: from suppliers whose quality control you cannot inspect, with no pharmacist and no prescriber standing anywhere in between.

If you’re weighing whether to use any of these, the question hasn’t changed either. For the specific use you have in mind: how many human trials exist, and what did they find? That’s it. That’s the whole question.

Awake Inside Wellness offers select research-use-only peptides and may earn from some links on this site. We grade every compound on the same evidence scale whether or not we sell it. Educational content only, not medical advice. Talk to a qualified clinician before starting anything.